JP2022536687A5 - - Google Patents

Info

Publication number
JP2022536687A5
JP2022536687A5 JP2021573404A JP2021573404A JP2022536687A5 JP 2022536687 A5 JP2022536687 A5 JP 2022536687A5 JP 2021573404 A JP2021573404 A JP 2021573404A JP 2021573404 A JP2021573404 A JP 2021573404A JP 2022536687 A5 JP2022536687 A5 JP 2022536687A5
Authority
JP
Japan
Application number
JP2021573404A
Other languages
Japanese (ja)
Other versions
JP7677910B2 (ja
JPWO2020252129A5 (https=
JP2022536687A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037174 external-priority patent/WO2020252129A1/en
Publication of JP2022536687A publication Critical patent/JP2022536687A/ja
Publication of JPWO2020252129A5 publication Critical patent/JPWO2020252129A5/ja
Publication of JP2022536687A5 publication Critical patent/JP2022536687A5/ja
Priority to JP2025076158A priority Critical patent/JP2025131572A/ja
Application granted granted Critical
Publication of JP7677910B2 publication Critical patent/JP7677910B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573404A 2019-06-11 2020-06-11 腎機能障害を有する患者のファブリー病を治療する方法 Active JP7677910B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025076158A JP2025131572A (ja) 2019-06-11 2025-05-01 腎機能障害を有する患者のファブリー病を治療する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962859904P 2019-06-11 2019-06-11
US62/859,904 2019-06-11
PCT/US2020/037174 WO2020252129A1 (en) 2019-06-11 2020-06-11 Methods of treating fabry disease in patients having renal impairment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076158A Division JP2025131572A (ja) 2019-06-11 2025-05-01 腎機能障害を有する患者のファブリー病を治療する方法

Publications (4)

Publication Number Publication Date
JP2022536687A JP2022536687A (ja) 2022-08-18
JPWO2020252129A5 JPWO2020252129A5 (https=) 2023-06-20
JP2022536687A5 true JP2022536687A5 (https=) 2023-06-20
JP7677910B2 JP7677910B2 (ja) 2025-05-15

Family

ID=71950725

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573404A Active JP7677910B2 (ja) 2019-06-11 2020-06-11 腎機能障害を有する患者のファブリー病を治療する方法
JP2025076158A Pending JP2025131572A (ja) 2019-06-11 2025-05-01 腎機能障害を有する患者のファブリー病を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025076158A Pending JP2025131572A (ja) 2019-06-11 2025-05-01 腎機能障害を有する患者のファブリー病を治療する方法

Country Status (16)

Country Link
US (1) US20220313670A1 (https=)
EP (1) EP3982962A1 (https=)
JP (2) JP7677910B2 (https=)
KR (1) KR20220019796A (https=)
CN (1) CN114423427A (https=)
AR (1) AR120055A1 (https=)
AU (2) AU2020291002A1 (https=)
BR (1) BR112021024886A2 (https=)
CA (1) CA3141226A1 (https=)
CL (1) CL2021003280A1 (https=)
EA (1) EA202290024A1 (https=)
IL (1) IL288677A (https=)
MX (1) MX2021015352A (https=)
PH (1) PH12021553102A1 (https=)
TW (1) TW202112372A (https=)
WO (1) WO2020252129A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573498T3 (es) 2006-05-16 2016-06-08 Amicus Therapeutics, Inc. Opciones de tratamiento para la enfermedad de Fabry
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
CA3224537C (en) 2017-05-30 2025-09-09 Amicus Therapeutics, Inc. USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE
CA3090496C (en) 2018-02-06 2024-03-26 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
EP4282472A3 (en) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
EP3851105B1 (en) 2019-08-07 2026-03-04 Amicus Therapeutics, Inc. Migalastat for use in treating fabry disease in patients having a mutation in the gla gene
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
AU2008232614A1 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of Fabry disease using pharmacological chaperones
EP2150254A4 (en) * 2007-04-26 2010-11-10 Amicus Therapeutics Inc DOSAGES FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES WITH PHARMACOLOGICAL CHAPTERONES
SI3470077T1 (sl) 2008-02-12 2020-12-31 Amicus Therapeutics, Inc. Postopek za napovedovanje odgovora na zdravljenje bolezni s farmakološkim spremljevalcem
CN103974619B (zh) * 2011-03-11 2017-02-15 阿米库斯治疗学公司 治疗法布里病的给药方案
AR109103A1 (es) * 2016-07-19 2018-10-31 Amicus Therapeutics Inc Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
EP3565583A4 (en) * 2017-01-05 2020-12-02 Protalix Ltd. TREATMENT DIET FOR THE TREATMENT OF FABRY'S DISEASE USING STABILIZED ALPHA-GALACTOSIDASE
PT4324522T (pt) * 2017-05-30 2026-03-13 Amicus Therapeutics Inc Métodos de tratamento de pacientes com fabry tendo insuficiência renal
AR111971A1 (es) * 2017-05-30 2019-09-04 Amicus Therapeutics Inc Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal
CA3224537C (en) * 2017-05-30 2025-09-09 Amicus Therapeutics, Inc. USE OF MIGALASTAT IN THE TREATMENT OF PATIENTS WITH FABRY DISEASE AND RENAL FAILURE

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2022536687A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021016176A2 (https=)
BR102021015566A2 (https=)
BR102021015450A8 (https=)
BR102021015247A2 (https=)
BR102021015220A2 (https=)
BR102021014044A2 (https=)
BR102021014056A2 (https=)